Ilyang Pharmaceutical Completes First KRW 2.2 Billion Capital Injection into Chinese Subsidiary, Total KRW 17.6 Billion Investment Underway
Ilyang Pharmaceutical completed the first capital injection of USD 1.5 million approximately KRW 2.2 billion into its Chinese subsidiary Ilyang Pharmaceutical Jilin on June 30, 2026.
This is the first execution step of the previously announced total investment of RMB 80 million approximately KRW 17.6 billion, aimed at establishing a local production base for the product Wonbidi.
Since the subsidiary is wholly owned, no shareholder dilution occurs, and the investment is focused on long-term growth and market expansion in China.
Wonbidi generated approximately KRW 40.5 billion in China sales in 2023, and this investment is expected to strengthen competitiveness through local production.
[AI Summary]This amendment confirms the progress of the previously disclosed investment plan with no new share issuance or dilution. The total investment of 7.3% of equity is reasonable, and the production expansion in China aligned with existing revenue growth supports long-term shareholder value, though the subsidiary's zero current revenue limits near-term earnings contribution.
KOSPI Filing Information
[Correction of Description] Decision on Acquisition of Stocks and Equity Securities of Other Corporations